263 related articles for article (PubMed ID: 37844352)
21. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.
Gill H; Puramat P; Patel P; Gill B; Marks CA; Rodrigues NB; Castle D; Cha DS; Mansur RB; Rosenblat JD; McIntyre RS
Psychiatry Res; 2022 Jul; 313():114577. PubMed ID: 35580433
[TBL] [Abstract][Full Text] [Related]
22. Psilocybin for Trauma-Related Disorders.
Khan AJ; Bradley E; O'Donovan A; Woolley J
Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
[TBL] [Abstract][Full Text] [Related]
23. Next generation antidepressants with novel mechanisms for treatment resistant depression.
Chen MH; Tu PC; Su TP
Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
[TBL] [Abstract][Full Text] [Related]
24. Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis.
Ko K; Kopra EI; Cleare AJ; Rucker JJ
J Affect Disord; 2023 Feb; 322():194-204. PubMed ID: 36209780
[TBL] [Abstract][Full Text] [Related]
25. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
[TBL] [Abstract][Full Text] [Related]
26. [Contribution of serotonin 5-HT
Ibi D
Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
[TBL] [Abstract][Full Text] [Related]
27. Psychedelics and Psychedelic-Assisted Psychotherapy.
Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
[TBL] [Abstract][Full Text] [Related]
28. Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.
Haniff ZR; Bocharova M; Mantingh T; Rucker JJ; Velayudhan L; Taylor DM; Young AH; Aarsland D; Vernon AC; Thuret S
Pharmacol Ther; 2024 Jun; 258():108641. PubMed ID: 38583670
[TBL] [Abstract][Full Text] [Related]
29. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT
Sekssaoui M; Bockaert J; Marin P; Bécamel C
Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441
[TBL] [Abstract][Full Text] [Related]
30. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
[TBL] [Abstract][Full Text] [Related]
31. [Are psychedelics fast acting antidepressant agents?].
Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ
Nervenarzt; 2022 Mar; 93(3):254-262. PubMed ID: 35103814
[TBL] [Abstract][Full Text] [Related]
32. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.
Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266
[TBL] [Abstract][Full Text] [Related]
33. Intravenous psilocybin attenuates mechanical hypersensitivity in a rat model of chronic pain.
Kolbman N; Liu T; Guzzo P; Gilligan J; Mashour GA; Vanini G; Pal D
Curr Biol; 2023 Dec; 33(24):R1282-R1283. PubMed ID: 38113836
[TBL] [Abstract][Full Text] [Related]
34. [Classic psychedelic drugs and their potential therapeutic effect].
Bayat M
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
[TBL] [Abstract][Full Text] [Related]
35. Dose effect of psilocybin on primary and secondary depression: a preliminary systematic review and meta-analysis.
Li NX; Hu YR; Chen WN; Zhang B
J Affect Disord; 2022 Jan; 296():26-34. PubMed ID: 34587546
[TBL] [Abstract][Full Text] [Related]
36. Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients.
Shnayder S; Ameli R; Sinaii N; Berger A; Agrawal M
J Affect Disord; 2023 Feb; 323():592-597. PubMed ID: 36513161
[TBL] [Abstract][Full Text] [Related]
37. HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.
Lewis BR; Garland EL; Byrne K; Durns T; Hendrick J; Beck A; Thielking P
J Pain Symptom Manage; 2023 Sep; 66(3):258-269. PubMed ID: 37302533
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S
J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890
[TBL] [Abstract][Full Text] [Related]
39. Potential use of psilocybin drugs in the treatment of depression.
Śladowska K; Kawalec P; Brzostek T; Pilc A
Expert Opin Emerg Drugs; 2023 Dec; 28(4):241-256. PubMed ID: 37817501
[TBL] [Abstract][Full Text] [Related]
40. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
